CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Tedizolid phosphate

Tedizolid phosphate

Last Updated: January 16, 2015

Result type: Reports

Project Number: SR0413-000

Product Line: Reimbursement Review

Generic Name: Tedizolid phosphate

Brand Name: Sivextro

Manufacturer: Cubist Pharmaceuticals Canada, Inc.

Therapeutic Area: Acute bacterial skin and skin structure infections

Indications: Acute bacterial skin and skin structure infections

Submission Type: Initial

Project Status: Withdrawn

Tedizolid phosphate

Files